Where does Apellis Pharmaceuticals, Inc. rank among US patent assignees?

According to USPTO PatentsView (2015–2025 granted utility patents), Apellis Pharmaceuticals, Inc. ranks #12,348 of 49,997 assignees by granted-patent volume, the same sort as the companies listing and top-holders ranking. See /methodology/#corpus-placement.

How many patents does Apellis Pharmaceuticals, Inc. hold?

Apellis Pharmaceuticals, Inc. holds 24 US utility patents granted between 2016 and 2025, spanning 10 technology areas.

What is Apellis Pharmaceuticals, Inc.'s Innovation Score?

Apellis Pharmaceuticals, Inc. has an Innovation Score of 39.1 out of 100 (top 39% of the corpus). This composite metric weighs portfolio volume (40%), grant velocity (20%), technology breadth (25%), and claim depth (15%).

What technology areas does Apellis Pharmaceuticals, Inc. focus on?

Apellis Pharmaceuticals, Inc.'s top technology area is A61K (Preparations FOR Medical, Dental OR Toiletry Purposes) with 23 patents, ranking #978 of 7,163 assignees active in that subclass. Grants appear in 10 CPC subclasses total.

Is Apellis Pharmaceuticals, Inc.'s patent grant rate increasing or decreasing?

Apellis Pharmaceuticals, Inc.'s recent grant velocity is +114% compared to the prior five-year period (grant years, not application filing dates). This indicates accelerating grant output.

What does claim depth mean for Apellis Pharmaceuticals, Inc.'s patents?

Apellis Pharmaceuticals, Inc.'s patents average 15.6 claims each. This is an aggregate descriptive count from the grant record; it does not establish claim scope, legal strength, enforceability, or design-around risk.

How is the Apellis Pharmaceuticals, Inc. patent data sourced?

All patent data comes from USPTO PatentsView, a public research dataset maintained by the United States Patent and Trademark Office covering US granted utility patents from 2015 to 2025.

USPTO 2015–2025 USPTO PatentsView US Corporation

Apellis Pharmaceuticals, Inc.

USPTO PatentsView assignee record - 24 granted patents across 10 technology areas, recorded in grant years 2016–2025. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: A61K (Preparations FOR Medical, Dental OR Toiletry Purposes).

Compiled by PlainPatent · May 15, 2026

RSS updates for this company

Explore the portfolio See the ranking

The verdict

According to USPTO PatentsView, Apellis ranks #12,348 of 49,997 tracked US assignees by granted-patent volume, with 24 patents across 10 technology areas.

#12,348
of 49,997 US assignees by volume: Top 39%
by Innovation Score (39.1/100): 15.6
avg claims per patent: +114%
grant velocity, last 5 yrs

USPTO PatentsView assignee plate

Corpus R12348 · US Corporation #12,348 · 24 grants

GRANTS-SMALL · UPPER-Q · PHOTO-FINISH · CPC-FOCUS · INNOV-THIN · CLAIMS-RICH · TYPE-USCORP · VEL-SURGE · BOOK-FULL

GRANTS-SMALL 24 grants
UPPER-Q #12,348/49,997
PHOTO-FINISH Alpine Immune Sciences
CPC-FOCUS A61K · 10 areas
INNOV-THIN 39.1/100
CLAIMS-RICH 15.6 claims/avg
TYPE-USCORP US Corporation
VEL-SURGE +114% vel
BOOK-FULL 10/10 fields

Nearest grant-volume peer: Alpine Immune Sciences, Inc. (±0 grants)

Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.

How Apellis’s 39.1 Innovation Score adds up

The same four weighted components behind every Innovation Score on PlainPatent: portfolio volume, grant velocity, technology breadth, and claim depth.

Volume 11.1 pts (28%) Velocity 7.5 pts (19%) Breadth 11.2 pts (29%) Claim depth 9.3 pts (24%)

Qualcomm Incorporated · highest

85
Apellis Pharmaceutic… · this assignee

39
3D Lighting… · lowest

7

What this shows Apellis's Innovation Score is 39.1/100 (top 39% of the PatentsView-derived corpus). The chart places that score against the nearest Innovation Score peers plus corpus poles, not a reprint of the volume ranking.

Does more volume mean deeper claims for Apellis?

Each dot is one of Apellis’s 8 nearest volume peers (same corpus rank neighbourhood as the chart above), placed by total granted patents (horizontal) against average claims per patent (vertical). Apellis’s own 15.6 claims/patent is at or below the 18.6 median for these volume peers. Volume here does not track with deeper claims; several lower-volume peers claim more thoroughly per patent.

Apellis vs its 8 nearest volume peers: granted patents vs average claims per patent. Source: USPTO PatentsView.

Where Apellis's grants concentrate

Apellis Pharmaceuticals, Inc. is a focused PatentsView assignee: 10 CPC subclasses with 95.8% of grants classified under A61K (Preparations FOR Medical, Dental OR Toiletry Purposes). Peak complete grant year is 2022 (5 grants) versus a trough of 1 in 2024. By volume, Apellis sits between Alpine Immune Sciences, Inc. and Arkade, Inc..

Apellis's three-year grant acceleration

Apellis Pharmaceuticals, Inc. shows 9 grants in 2022–2024 against only 8 in 2019–2021. That prior window is too thin for a growth multiple (rename and spin-out assignees look artificially high when the baseline is near zero), so PlainPatent withholds a ranked acceleration claim here.

Alpine Immune Sci…

24
Ameriglobe

24
Amprius

24
Anonyome Labs

24
Arqule

24
Archem

24
Archroma IP

24
Arkade

24
Apellis Pharmaceu… ◀

24

What this shows Apellis holds 24 patents at rank #12,354, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.

Companies ranked near Apellis

By rank, the assignees closest to #12,354 in granted patent volume.

Leaders in A61K (Preparations FOR Medical)

Other assignees with the most granted patents in Apellis's primary technology class.

Apellis's Innovation Score vs. every tracked assignee

Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)

39 Top 39% higher than 61% of 49,997 US assignees

Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025

USPTO utility patent grants by year · 2016–2025

Grants by year

Teal-shaded recent years (2020–present) versus the 2016–2019 baseline. Full figures in the table below.

View data table

Apellis Pharmaceuticals, Inc. patent grants by year, 2015–2025
Year	Patents Granted	Share of Period
2016	2	8.3%
2018	3	12.5%
2019	2	8.3%
2020	2	8.3%
2021	4	16.7%
2022	5	20.8%
2023	3	12.5%
2024	1	4.2%
2025partial year	2	8.3%

Which technologies does Apellis Pharmaceuticals, Inc. patent most?

A61K - Preparations FOR Medical, Dental OR Toiletry Purposes 23

A61P - Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations 20

C07K - Peptides 19

G01N - Investigating OR Analysing Materials BY Determining Their Chemical OR Physical Properties 9

C12N - Microorganisms OR ENZYMES; Compositions THEREOF; Propagating, Preserving, OR Maintaining MICROORGANISMS; Mutation OR Genetic ENGINEERING; Culture Media 6

A61B - DIAGNOSIS; SURGERY; Identification 4

A61F - Filters Implantable Into Blood VESSELS; PROSTHESES; Devices Providing Patency TO, OR Preventing Collapsing OF, Tubular Structures OF THE Body, e.g. STENTS; Orthopaedic, Nursing OR Contraceptive DEVICES; FOMENTATION; Treatment OR Protection OF Eyes OR EARS; Bandages, Dressings OR Absorbent PADS; Firs 3

A01N - Preservation OF Bodies OF Humans OR Animals OR Plants OR Parts Thereof ; Biocides, e.g. AS Disinfectants, AS Pesticides OR AS Herbicides ; Pest Repellants OR ATTRACTANTS; Plant Growth Regulators 2

A61M - Devices FOR Introducing Media Into, OR Onto, THE Body ; Devices FOR Transducing Body Media OR FOR Taking Media From THE Body ; Devices FOR Producing OR Ending Sleep OR Stupor 2

C12Q - Measuring OR Testing Processes Involving Enzymes, Nucleic Acids OR Microorganisms ; Compositions OR Test Papers THEREFOR; Processes OF Preparing Such COMPOSITIONS; Condition-responsive Control IN Microbiological OR Enzymological Processes 1

Top 10 of 10 technology areas

More on this record

Data Source

USPTO PatentsView, US granted patents 2015–2025

View all rankings → How is Innovation Score calculated?

What to do with this data

Apellis Pharmaceuticals, Inc.'s patent record in context - here's where to go next.

Apellis Pharmaceuticals, Inc.'s lead technology class is A61K (Preparations FOR Medical, Dental OR Toiletry Purposes), 95.8% of its portfolio - see every assignee active in that class. Explore A61K
Ranked #12,348 of 49,997 tracked assignees by patent volume - see the full leaderboard. See the ranking
Compare Apellis Pharmaceuticals, Inc. against Alpine Immune Sciences, Inc., an assignee filing at a similar volume. Compare portfolios
Innovation Score of 39.1/100 blends volume, velocity, technology breadth, and claim depth. How it's calculated

Figures reflect USPTO PatentsView grant data through May 2026; pending applications not yet granted are not counted.

Data sourced from USPTO PatentsView - official U.S. government patent data. See our methodology for computation details. Retrieved and formatted by PlainPatent

Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the USPTO PatentsView database. Consult a qualified professional before making decisions based on this data.

Read our methodology - how this data is sourced, computed, and verified.

Data sources used on this page

USPTO PatentsView - the disambiguated bulk patent-grant, assignee, and CPC data this page's figures are derived from. patentsview.org
Cooperative Patent Classification (CPC) - the joint USPTO/EPO classification scheme used to group patents by technology area. cooperativepatentclassification.org
USPTO Patent Public Search - the official interface to verify the status of any individual patent. ppubs.uspto.gov

Compiled by PlainPatent, US Patent Intelligence Editorial Process · May 15, 2026

Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.